Ozempic Should Not Be Used for Weight Loss in Someone with a BMI of 23
A person with a BMI of 23 does not meet FDA-approved criteria for Ozempic or any weight management medication and should not receive it for weight loss purposes. This BMI falls within the normal weight range and is well below the regulatory threshold for pharmacologic weight management.
FDA-Approved Indications Are Clear
The FDA has approved weight management medications, including semaglutide, only as adjuncts to lifestyle intervention in individuals with:
- BMI ≥30 kg/m² (obesity), OR
- BMI ≥27 kg/m² with one or more obesity-associated comorbid conditions (e.g., type 2 diabetes, hypertension, dyslipidemia) 1, 2
A BMI of 23 falls significantly below both thresholds and represents a normal, healthy weight range for most populations 1.
Clinical Trial Evidence Excludes This Population
All major semaglutide weight loss trials specifically enrolled participants with much higher BMI:
- STEP 1 and STEP 3 trials: Mean BMI of 38, with inclusion criteria requiring BMI ≥30 or ≥27 with comorbidities 2, 3
- SELECT trial: Required BMI ≥27 with established cardiovascular disease 4
- Real-world cohort studies: Included patients with mean BMI of 41.3 5
There is no safety or efficacy data for semaglutide use in individuals with BMI of 23 3, 5.
Significant Safety Concerns at Normal Weight
Using GLP-1 receptor agonists in normal-weight individuals carries substantial risks:
Risk of Malnutrition and Sarcopenia
- Incretin pharmacotherapies may increase risk for malnutrition and sarcopenia, particularly concerning in those without excess adipose tissue 1
- Individuals experiencing significant weight loss (>20%) or rapid weight loss (>4 kg/month) should be screened for malnutrition 1
Micronutrient Deficiencies
- GLP-1 receptor agonists are associated with vitamin D deficiency (13.6% at 12 months), iron depletion (26-30% lower ferritin levels), and inadequate calcium and protein intake 6
- These deficiencies contribute to lean mass loss, which would be particularly harmful in someone already at normal weight 6
Gastrointestinal Adverse Events
- Nausea occurs in 17-44% of users, diarrhea in 16-32%, vomiting in 7-25%, and constipation in 10-23% 2
- These side effects lead to treatment discontinuation in 4.5% of users 2
Common Pitfall: Off-Label Use for Cosmetic Weight Loss
The increasing popularity of GLP-1 receptor agonists has led to inappropriate off-label prescribing for cosmetic weight loss in normal-weight individuals. This practice:
- Lacks evidence-based support
- Exposes patients to unnecessary risks
- Diverts medication from those with medical indications
- May result in unhealthy weight loss below optimal BMI ranges
The Bottom Line
Ozempic is contraindicated for weight loss in someone with a BMI of 23. This individual does not have obesity or overweight by any clinical definition 1, 2. Prescribing weight loss medication to normal-weight individuals represents inappropriate medical practice that prioritizes cosmetic concerns over evidence-based medicine and patient safety. If weight concerns exist at this BMI, evaluation for body dysmorphia or eating disorders may be more appropriate than pharmacotherapy.